Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Oncotype DX Genomic Prostate Score® Assay

Laboratory Developed Test
Related tests:
The Oncotype DX Genomic Prostate Score (GPS) assay is the only genomic assay designed for men with clinically low-risk or favorable intermediate-risk cancer to help make treatment decisions at the time of diagnosis. The assay analyzes prostate cancer gene activity to predict disease aggressiveness. It examines interactions among genes in the tumor to better understand the unique biology of the cancer—a science known as genomics—for prostate cancer patients. The assay provides a GPS result ranging from 0-100 that corresponds to the biologic aggressiveness of the tumor and measures biology through the expression of 17 genes across four important genetic pathways and, in conjunction with clinical risk factors, predicts the likelihood of adverse pathology, prostate cancer death, and metastasis at 10 years.
Prostate Cancer
ARF1 (ADP Ribosylation Factor 1), ATP5F1E (ATP Synthase F1 Subunit Epsilon), AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding), BGN (Biglycan), CLTC (Clathrin Heavy Chain), COL1A1 (Collagen Type I Alpha 1 Chain)
See More ...